title: A case of psoriasis pustolosa palmaris induced by cetuximab.
abstract: Cetuximab is a monoclonal antibody that competitively inhibits the epidermal growth factor receptor (EGFR). It is used for the treatment of metastatic colorectal cancer after first-line therapy. We report the first case of a pustular psoriasiform drug eruption induced by cetuximab in a patient with colorectal cancer. This paradoxical side effect could be the result of an imbalance in downstream molecular pathways due to the EGFR signal blockade that could, in selected patients, induce alternative signalling pathways related to keratinocyte proliferation.
authors.affiliation: Unit of Dermatology, University of Padua, Padova, Italy.
authors.forename: Elena
authors.initials: E
authors.lastname: Marinello
authors.affiliation: Veneto Institute of Oncology, IOV-IRCCS, Padova, Italy.
authors.forename: Davide
authors.initials: D
authors.lastname: Pastorelli
authors.affiliation: Unit of Dermatology, University of Padua, Padova, Italy.
authors.forename: Mauro
authors.initials: M
authors.lastname: Alaibac
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D049109:Cell Proliferation; D000068818:Cetuximab / Q000009:adverse effects* / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D019008:Drug Resistance, Neoplasm; D066246:ErbB Receptors / Q000378:metabolism*; D006801:Humans; D015603:Keratinocytes / Q000187:drug effects; D008297:Male; D011565:Psoriasis / Q000209:etiology* / Q000378:metabolism; D015398:Signal Transduction; D012867:Skin / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; C512478:EGFR protein, human; D066246:ErbB Receptors; D000068818:Cetuximab